News

The patients who underwent the outpatient transplantation surgery were treated in the third patient cohort of each of the two trials that commenced in July 2011. A 150,000

The investigational recombinant human tripeptidyl peptidase 1, BMN-190, is being developed as a medication for a form of Batten disease called neuronal ceroid lipofuscinosis type 2 (NCL-2). The

The agreement will leverage Ra Pharmaceuticals’ Extreme Diversity platform for the development of peptide-like molecules with antibody diversity and specificity called Cyclomimetics. Ra Pharmaceuticals co-founder, president and CEO

The Court also said that the generic defendants involved in the litigation do not conflict AstraZeneca’s second patent. AstraZeneca North America division executive vice president Paul Hudson said

SmartParts act as the building blocks for the company’s next generation of bioreactor controller systems that have plug-and-play capability and can control any size or type of upstream

Following funding from the DoD, the UK-based Euprotec is collaborating with Mauritius-based Fulhold and the New Jersey Medical School-UMDNJ to assess a topical broad spectrum antimicrobial agent for

The sanction involves the temporary suspension of Takeda’s activities as chairman of GMP Committee and vice chairman of Pharmaceutical Laws and Regulations Committee of OPMA for the period

The company expects to make the flavored asthma medicine, with grape taste and higher strength, soon available for patients throughout the country. Mission Pharmacal Company Pediatric Rx Products

CV9104, the RNActive cancer vaccine, encodes antigens that are overexpressed in prostate cancer. University of Tubingen, Germany, urology department medical director and the study coordinating investigator Arnulf Stenzl